Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | IL17A | Q16552 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 4/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22125806 | 1.00 | MEN1 (0.42) | MEN1KMT2AIL17AJAK2AAK1 | |
| SCHEMBL22143737 | 0.88 | MEN1 (0.39) | MEN1KMT2AIL17AJAK2AAK1 | |
| SCHEMBL29895007 | 0.88 | MEN1 (0.38) | MEN1KMT2AIL17AJAK2AAK1 | |
| SCHEMBL22144039 | 0.88 | MEN1 (0.38) | MEN1KMT2AIL17AJAK2AAK1 | |
| SCHEMBL22125804 | 0.88 | MEN1 (0.38) | MEN1KMT2AIL17AJAK2AAK1 | |
| SCHEMBL28606581 | 0.86 | AAK1 (0.44) | MEN1KMT2AJAK2AAK1PTPN2 | |
| SCHEMBL24593528 | 0.85 | AAK1 (0.44) | MEN1KMT2AJAK2AAK1 | |
| SCHEMBL22143981 | 0.85 | AAK1 (0.44) | MEN1KMT2AJAK2AAK1 | |
| SCHEMBL28603119 | 0.85 | AAK1 (0.44) | MEN1KMT2AJAK2AAK1 | |
| SCHEMBL28603117 | 0.85 | AAK1 (0.44) | MEN1KMT2AJAK2AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377425-B1 | Small molecule modulators of IL-17 | LEO PHARMA A/S (DK) | 2022-07-05 | — | — | US | disclosed |
| CN-113164448-A | Amino acid anilines as small molecule modulators of IL-17 | 利奥制药有限公司 | 2021-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377425-B1 | Small molecule modulators of IL-17 | IL17A, IL15, IL2 | MEN1 2191/4885KMT2A 3095/4885IL17A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.